The Artificial Blood Market is estimated at US$2 billion in 2026 and is projected to grow at a CAGR of 9.7% to reach US$4.2 billion by 2034.
Core applications include trauma support, battlefield medicine, blood shortage mitigation, surgical backup, emergency transport care, and research into transfusion alternatives. Demand reflects the need for transfusion alternatives, blood supply limitations, emergency care logistics, and demand for portable oxygen carrying options in remote or time critical.
This product will be delivered within 1-3 business days.
Market Overview
The Artificial Blood Market covers oxygen carrying blood substitute technologies and related development programs intended to support transfusion alternatives, emergency care, military medicine, and specialized clinical applications. Its value chain includes biotech developers, hemoglobin processing specialists, contract manufacturers, hospitals, defense health systems, regulators, and research institutions.Core applications include trauma support, battlefield medicine, blood shortage mitigation, surgical backup, emergency transport care, and research into transfusion alternatives. Demand reflects the need for transfusion alternatives, blood supply limitations, emergency care logistics, and demand for portable oxygen carrying options in remote or time critical.
Key Companies Analysed
- Hemarina
- HbO2 Therapeutics
- Sanguine Biosciences
- KaloCyte
- Aurea Biolabs
- MediWound
- Baxter
- Biopure
- Northfield Laboratories
- HemoBioTech
- Sangart
- Vitaeris
- CSL
- Takeda
- Grifols
- Octapharma
- Biotest
- LFB
- Kedrion
- Oxyvita
Geographic Coverage
- North America - Market data and outlook to 2034
- United States
- Canada
- Mexico
- Europe - Market data and outlook to 2034
- Germany
- United Kingdom
- France
- Italy
- Spain
- Netherlands
- Switzerland
- Poland
- Sweden
- Russia
- Asia-Pacific - Market data and outlook to 2034
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Malaysia
- Vietnam
- Middle East and Africa - Market data and outlook to 2034
- Saudi Arabia
- South Africa
- Iran
- UAE
- Egypt
- South and Central America - Market data and outlook to 2034
- Brazil
- Argentina
- Chile
- Peru
Report Delivery and Support
- Updated PDF report and an MS Excel workbook containing market tables and figures.
- 7-day post-sale analyst support for clarifications and in-scope supplementary data.
- Complimentary report update covering the latest available data and relevant market developments.
This product will be delivered within 1-3 business days.
Table of Contents
1. Contents and Report Guide
2. Global Artificial Blood Market Overview
3. Artificial Blood Market Dynamics
4. Artificial Blood Market Strategic Analysis
5. Global Artificial Blood Market Size, Share and Forecast, 2025-2034
6. North America Artificial Blood Market Outlook to 2034
7. Europe Artificial Blood Market Outlook to 2034
8. Asia-Pacific Artificial Blood Market Outlook to 2034
9. Middle East and Africa Artificial Blood Market Outlook to 2034
10. South and Central America Artificial Blood Market Outlook to 2034
11. Artificial Blood Market Competitive Landscape
12. Appendix
Companies Mentioned
- Hemarina
- HbO2 Therapeutics
- Sanguine Biosciences
- KaloCyte
- Aurea Biolabs
- MediWound
- Baxter
- Biopure
- Northfield Laboratories
- HemoBioTech
- Sangart
- Vitaeris
- CSL
- Takeda
- Grifols
- Octapharma
- Biotest
- LFB
- Kedrion
- Oxyvita
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 160 |
| Published | October 2026 |
| Forecast Period | 2026 - 2034 |
| Estimated Market Value ( USD | $ 2 Billion |
| Forecasted Market Value ( USD | $ 4.2 Billion |
| Compound Annual Growth Rate | 9.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 20 |
